Rudd SG

JSON
CSV
XLSX
TXT
Family name Rudd
Given name Sean G
Initials SG
ORCID

ORCID 0000-0002-4368-3855
Affiliations Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

27 publications

PubMed DOI Crossref
Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.
Klootsema Y, Tsesmetzis N, Sharma S, ..., Lilienthal I, Herold N
Cell Cycle 25 (1) 1-19 [2026-12-00; online 2025-12-15]
DOI Crossref
NUDT5 regulates the global efficacy of nucleoside analog drugs by coordinating purine synthesis and PRPP allocation
Valerie NCK, Alam S, Hormann FM, ..., Arvidsson PI, Altun M
- - (-) - [2025-11-20; online 2025-11-20]
PubMed DOI Crossref
Repurposing Asparaginase Therapy to Target Cisplatin-Resistant Cancer Cells.
Wang J, Pouryaghoub N, Strauss R, ..., Zhang SM, Rudd SG
Fundam Clin Pharmacol 39 (5) e70044 [2025-10-00; online 2025-08-11]
DOI Crossref
Uridine cytidine kinases dictate the therapeutic response of molnupiravir via its bioactivation
Shu H, Sharm S, Alam S, ..., Rudd SG, Zhang SM
- - (-) - [2025-05-14; online 2025-05-14]
PubMed DOI Crossref
Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
Hormann FM, Rudd SG
Leukemia 39 (3) 531-542 [2025-03-00; online 2025-02-17]
PubMed DOI Crossref
Understanding the interplay between dNTP metabolism and genome stability in cancer.
Yagüe-Capilla M, Rudd SG
Dis Model Mech 17 (8) - [2024-08-01; online 2024-08-29]
DOI Crossref
Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy
Wang J, Strauss R, Bartek J, Rudd SG
- - (-) - [2024-07-22; online 2024-07-22]
PubMed DOI Crossref
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.
Rudd SG
Cancer Chemother. Pharmacol. 92 (4) 241-251 [2023-10-00; online 2023-07-15]
DOI Crossref
Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel
Zhang SM, Paulin CBJ, Michel M, ..., Helleday T, Rudd SG
- - (-) - [2023-01-18; online 2023-01-18]
PubMed DOI Crossref
Targeting the DNA damage response and repair in cancer through nucleotide metabolism.
Helleday T, Rudd SG
Mol Oncol 16 (21) 3792-3810 [2022-11-00; online 2022-05-28]
PubMed DOI Crossref
Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Ceder S, Eriksson SE, Liang YY, ..., Rudd SG, Wiman KG
Cell Death Dis 13 (8) 672 [2022-08-03; online 2022-08-03]
PubMed DOI Crossref
The prognostic and clinicopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis.
Wang J, Hao S, Gu J, Rudd SG, Wang Y
PeerJ 10 (-) e13141 [2022-03-22; online 2022-03-22]
PubMed DOI Crossref
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Ceder S, Eriksson SE, Liang YY, ..., Rudd SG, Wiman KG
Cell Death Dis 12 (7) 709 [2021-07-15; online 2021-07-15]
PubMed DOI Crossref
Drug synergy scoring using minimal dose response matrices.
Mäkelä P, Zhang SM, Rudd SG
BMC Res Notes 14 (1) 27 [2021-01-19; online 2021-01-19]
DOI Crossref
Drug synergy scoring using minimal dose response matrices
Mäkelä P, Zhang SM, Rudd SG
- - (-) - [2020-10-31; online 2020-10-31]
PubMed DOI Crossref
Development of a chemical probe against NUDT15.
Zhang SM, Desroses M, Hagenkort A, ..., Stenmark P, Helleday T
Nat. Chem. Biol. 16 (10) 1120-1128 [2020-10-00; online 2020-07-20]
PubMed DOI Crossref
MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.
Rudd SG, Gad H, Sanjiv K, ..., Berglund UW, Helleday T
Cancer Res. 80 (17) 3530-3541 [2020-09-01; online 2020-04-20]
DOI Crossref
SAMHD1 promotes oncogene-induced replication stress
Zhang SM, Calderón-Montaño JM, Rudd SG
- - (-) - [2020-07-29; online 2020-07-29]
PubMed DOI Crossref
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG, Tsesmetzis N, Sanjiv K, ..., Helleday T, Herold N
EMBO Mol Med 12 (3) e10419 [2020-03-06; online 2020-01-17]
PubMed DOI Crossref
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.
Page BDG, Valerie NCK, Wright RHG, ..., Beato M, Helleday T
Nat Commun 10 (1) 5050 [2019-11-01; online 2019-11-01]
DOI Crossref
MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells
Gad H, Mortusewicz O, Rudd SG, ..., Berglund UW, Helleday T
- - (-) - [2019-03-12; online 2019-03-12]
DOI Crossref
MTH1 inhibitor TH588 induces mitosis-dependent accumulation of genomic 8-oxodG and disturbs mitotic progression
Rudd SG, Gad H, Amaral N, ..., Berglund UW, Helleday T
- - (-) - [2019-03-12; online 2019-03-12]
PubMed DOI Crossref
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Rassidakis GZ, Herold N, Myrberg IH, ..., Xagoraris I, Khoury JD
Blood Cancer J 8 (11) 98 [2018-10-19; online 2018-10-19]
PubMed DOI Crossref
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.
Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N
Cancers (Basel) 10 (7) - [2018-07-23; online 2018-07-23]
PubMed DOI Crossref
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.
Page BDG, Valerie NCK, Wright RHG, ..., Beato M, Helleday T
Nat Commun 9 (1) 250 [2018-01-17; online 2018-01-17]
PubMed DOI Crossref
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
Herold N, Rudd SG, Sanjiv K, ..., Henter JI, Schaller T
Cell Cycle 16 (11) 1029-1038 [2017-06-03; online 2017-04-24]
PubMed DOI Crossref
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
Rudd SG, Schaller T, Herold N
Mol Cell Oncol 4 (2) e1287554 [2017-02-03; online 2017-02-03]
SciLifeLab Data Centre
Publications 9.5.1